Coastlands Capital LP and Affiliates File Schedule 13D for X4 Pharmaceuticals, Inc.

Coastlands Capital LP, along with its affiliates Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, have filed a Schedule 13D with the SEC regarding their holdings in X4 Pharmaceuticals, Inc. The filing discloses that the Reporting Persons collectively beneficially own 9.99% of the outstanding Common Stock of X4 Pharmaceuticals, representing 2,479,645 shares. This ownership includes 107,500 shares of Common Stock and a pre-funded warrant exercisable for up to 7,047,216 shares of Common Stock. The Reporting Persons acquired these securities through the August 2025 Financing, where Coastlands purchased a pre-funded warrant for $9,999,999.50. The filing also details the terms of the pre-funded warrant, including an exercise price of $0.001 per share and a Beneficial Ownership Blocker that limits the Reporting Persons' ownership to 9.99% of the outstanding Common Stock. Additionally, the Reporting Persons have entered into a resale registration rights agreement with X4 Pharmaceuticals to facilitate the resale of their shares.